IP Cases — 2024
4,762 decisions across all jurisdictions
Page 5 of 159 · 4,762 total
POSCO Co., Ltd. et al. v.ArcelorMittal
POSCO Co., Ltd. successfully petitioned the PTAB to institute an IPR against ArcelorMittal's patent, demonstrating a reasonable likelihood of prevailing on all 25 challenged claims. The Board found sufficient evidence across multiple grounds of obviousness (103) involving various prior art combinations.
Stingray Group Inc. et al. v.Hernandez-Mondragon, Edwin et al.
Stingray Group Inc. successfully secured institution of its IPR challenge against a patent covering multimedia content delivery systems. The Board found that Petitioner established a reasonable likelihood of prevailing across multiple grounds under 35 U.S.C. §§ 102 and 103, moving the case to the merits phase.
Tesla, Inc. v.Intellectual Ventures II LLC
The PTAB denied Tesla's IPR against Intellectual Ventures II over patent 7,181,743. The Board found that the prior art did not teach or suggest the specific 'event correlation capabilities' required by the challenged claims.
Twitch Interactive, Inc. et al. v.Razdog Holdings LLC
Twitch Interactive successfully challenged a patent claim in the PTAB, demonstrating a reasonable likelihood of prevailing on obviousness grounds. The Board adopted Petitioner's narrow construction of 'real time,' favoring transmission upon availability without significant delay over strict human-perception timing.
Twitch Interactive, Inc. et al. v.Razdog Holdings LLC
Twitch Interactive successfully secured institution of its § 103 IPR challenge against Razdog Holdings LLC's patent. The Board adopted the Petitioner's interpretation of 'real time,' allowing the case to proceed to trial on all claims.
M/S GREENPLY INDUSTRIES LTD. v.M/S EVERGREEN VENEERS PVT. LTD.
The plaintiff, Greenply Industries Ltd., filed a suit seeking permanent injunction for alleged infringement of its registered trade mark 'GREEN' against the defendant, Evergreen Veneers Pvt. Ltd., who was using the mark 'EVERGREEN' on similar goods (plywood products). The court examined issues of delay and trademark similarity.
Evergreen Sweet House v.JV Evergreen Sweets And Treats & Ors.
The Delhi High Court granted an interim injunction in favor of Evergreen Sweet House against JV Evergreen Sweets And Treats. The court found a prima facie case of passing off, noting that the plaintiff has been operating under the 'Evergreen' mark since 1963, establishing significant goodwill and prior use. Given the defendant's recent entry into the market and the likelihood of customer confusion on food delivery platforms, the court restrained the defendants from using the infringing mark until the final suit adjudication.
Saint Gobain Construction Products UK Ltd. v.Mr.Tallam Uma Shankar Gupta
The Madras High Court allowed a petition seeking rectification of the Trade Marks Register, directing the removal of the mark 'GYPLOCK' (No. 3536418). The petitioner, Saint Gobain Construction Products UK Ltd., successfully argued that its established trademark 'GYPROC' was similar to the impugned mark and used on identical goods—building materials. Despite arguments regarding common trade terms ('GYP'), the court found the overall similarity between 'GYPROC' and 'GYPLOCK' likely to cause confusion, thereby protecting the purity of the register.
pharma-aktiva GmbH, Hofer Kommanditgesellschaft, ALDI Nord Deutschland Stiftung & Co. KG, ALDI SE & Co. KG, ALDI SÜD Dienstleistungs-SE & Co. oHG v.G. Pohl-Boskamp GmbH & C. KG
G. Pohl-Boskamp GmbH & Co. KG, a pharmaceutical company marketing the head lice treatment NYDA®, filed an application for preliminary measures against pharma-aktiva GmbH and several ALDI group entities (ALDI SÜD, ALDI Nord, ALDI SE & Co. KG, and Hofer KG) for alleged infringement of European Patent EP 1 993 363 B1, which concerns a composition for combating ectoparasites and their eggs. The applicant challenged the sale of a competing lice spray marketed as 'Vitalis Läuse Spray' in Germany and 'ACTIV MED Läusespray' in Austria. The Local Chamber Mannheim issued an order on December 20, 2024, following an oral hearing on December 12, 2024, addressing the application for interim measures under Rule 206 RoP.
Alexion Pharmaceuticals, Inc. v.Samsung Bioepis NL B.V.
The Court of Appeal of the Unified Patent Court rejected Alexion Pharmaceuticals' appeal against the dismissal of its application for provisional measures against Samsung Bioepis concerning European Patent EP 3 167 888 B1 for a C5-binding antibody (eculizumab) used to treat paroxysmal nocturnal hemoglobinuria. The court held that the patent's claim 2 could not be corrected by interpretation to remove 22 extra amino acids at the N-terminus of SEQ ID NO:4, as the existence of the error and the precise correction were not sufficiently certain to the person skilled in the art. Consequently, the court found it more likely than not that claim 2 was insufficiently disclosed under Art. 83 EPC, and ordered Alexion to bear the costs of the appeal proceedings.
HARTING Electric Stiftung & Co. KG v.Respondent
This procedural order concerns an application by HARTING Electric Stiftung & Co. KG for access to the case files of an ongoing patent infringement action between PHOENIX CONTACT GmbH & Co. KG (plaintiff) and Industria Lombarda Materiale Elettrico I.L.M.E. S.p.A. and ILME GmbH (defendants) concerning European Patent EP 3 602 692. HARTING, which had filed an opposition against the patent in suit before the European Patent Office (joined by defendant ILME GmbH), sought access to the briefs and evidence filed in the main infringement proceedings to properly defend its interests in both the opposition proceedings and related utility model infringement actions. The Local Chamber Munich held that an opponent in a pending opposition proceeding concerning the patent in suit has a legal interest in accessing the case files under Rule 262.1(b) RoP during the ongoing proceedings.
Edwards Lifesciences Corporation v.Meril GmbH, Meril Life Sciences Pvt. Ltd., Meril Italy S.r.l.
Procedural order in a patent infringement action concerning European patent EP 3669828 before the Local Division Munich. The court granted both parties' Rule 263 requests to add Romania (which acceded to the Unitary Patent system on 1 September 2024) to the infringement action and counterclaim for revocation, and granted the claimant's request to amend its information request to require purchase documents. The court set the dispute value at €16 million, scheduled the oral hearing for 11 February 2025, and rejected requests for party and court experts.
President and Fellows of Harvard College v.Respondent
This case concerns a patent infringement action (UPC_CFI_22/2023) involving European Patent EP4108782, owned by President and Fellows of Harvard College, against Vizgen, Inc. The dispute centers on Plaintiff Harvard's third request to amend the patent, filed on October 25, 2024, which was rejected by the Rapporteur's order of November 8, 2024. The Local Chamber Hamburg reviewed the order under Rule 333.1 RoP and confirmed the rejection, holding that approximately three months between the alleged reason for the amendment and the filing of the request was too long under Rule 30.2 RoP.
Alexion Pharmaceuticals, Inc. v.Amgen Technology (Ireland) Unlimited Company, Amgen N.V., Amgen GmbH, Amgen AB, Amgen S.A.S., Amgen s.r.l., Amgen Biofarmacêutica Lda., Amgen Zdravila D.O.O.
Alexion Pharmaceuticals, the proprietor of European Patent 3 167 888 B1 relating to the antibody eculizumab for treating paroxysmal nocturnal hemoglobinuria, sought provisional measures against Amgen, which markets BEKEMV®, a biosimilar of Soliris®. The Court of First Instance (Hamburg Local Division) dismissed Alexion's application, and Alexion appealed. The Court of Appeal rejected the appeal, holding that the patent's SEQ ID NO:4 sequence must be interpreted as including 22 extra amino acids at the N-terminus, and that Alexion had failed to demonstrate with sufficient certainty that the skilled person would correct this as an error, rendering the patent claim more likely than not insufficiently disclosed under Art. 83 EPC.
Stingray Group Inc. et al. v.Hernandez-Mondragon, Edwin et al.
The PTAB notified parties that Director Review requests for three IPRs have been received. The petitioner has five business days to submit a concise response limited to the raised issues, with no new evidence allowed.
Stingray Group Inc. et al. v.Hernandez-Mondragon, Edwin et al.
The PTAB issued an institution decision for IPR2025-00349 on June 13, 2025. A later director‑review request by the patent owner was filed after the 14‑day deadline and was deemed untimely, so the Board will not consider it.
Webgroup Czech Republic, a.s. et al. v.DISH Technologies L.L.C. et al.
The USPTO denied Webgroup Czech Republic's request for Director Review of the Final Written Decisions in two IPRs challenging DISH Technologies patents.
Webgroup Czech Republic, a.s. et al. v.DISH Technologies L.L.C. et al.
The PTAB instituted inter partes review of DISH Technologies' adaptive‑bitrate streaming patent (claims 1‑16) and granted joinder to Webgroup Czech Republic and NKL Associates, aligning the case with the earlier fuboTV/MasterClass IPR.
Microsoft Corporation v.EyesMatch Ltd.
Microsoft and EyesMatch filed a joint request to keep their settlement agreement confidential, invoking federal statutes. The Board had previously authorized the filing, and the parties seek limited disclosure only to government agencies or parties with good cause.
Microsoft Corporation v.EyesMatch Ltd.
Microsoft and EyesMatch have settled their IPR dispute over U.S. Patent 8,982,110, filing a joint motion to terminate the proceeding.
Microsoft Corporation v.EyesMatch Ltd.
Microsoft and EyesMatch settled their IPR dispute over patent 8,982,109. The Board granted a joint motion to terminate the proceeding and sealed the settlement agreement as confidential business information.
Microsoft Corporation v.EyesMatch Ltd.
The PTAB instituted an inter partes review of Microsoft’s challenge to all 18 claims of EyesMatch’s ’109 patent and granted Microsoft’s motion to join the earlier IPR2024‑00856, consolidating the proceedings.
Microsoft Corporation v.EyesMatch Ltd.
Microsoft and EyesMatch settled their IPR dispute over U.S. Patent 8,982,110 B2. The Board granted a joint motion to terminate the proceeding and sealed the settlement agreement as confidential.
Stingray Group Inc. et al. v.Hernandez-Mondragon, Edwin et al.
Stingray Group and Stingray Music contest a late Director review request concerning a music‑licensing patent, urging the PTAB to deny the request on procedural and substantive grounds. The petitioners highlight the patent’s lack of commercialization and the improper submission of new evidence.
Microsoft Corporation et al. v.X1 Discovery, Inc.
The PTAB denied X1 Discovery’s request for an extension to file Director Review briefs in three IPRs against Microsoft, finding no good cause and emphasizing the need for timely filing.
Stingray Group Inc. et al. v.Hernandez-Mondragon, Edwin et al.
Stingray Group has filed an IPR petition seeking cancellation of all claims of U.S. Patent 10,524,002, arguing they are obvious or anticipated by earlier web‑broadcast technologies. The petition cites Avellan, Ma, Fain, and Wannamaker as prior art and requests that the Board institute the review.
Microsoft Corporation v.ParTec AG
Microsoft seeks to invalidate ParTec’s 11,537,442 patent covering dynamic task allocation in heterogeneous clusters, arguing the claims are obvious over prior‑art references Lippert, Budenske, and Kambatla. The petition also challenges a potential Fintiv denial.
Microsoft Corporation et al. v.X1 Discovery, Inc.
Microsoft has filed an IPR petition seeking cancellation of all 20 claims of X1 Discovery’s U.S. Patent No. 10,552,490 covering search indexing. The petition argues the claims are obvious over Lotus Notes, Raskin, Wu, Entourage, True, and Baeza‑Yates references and urges the Board not to deny institution.
Stingray Group Inc. et al. v.Hernandez-Mondragon, Edwin et al.
The PTAB granted institution for the IPR against U.S. Patent 10,123,074, finding a reasonable likelihood of unpatentability based on Avellan. The decision confirmed that 'content provider' does not require originating the request.
Microsoft Corporation v.ParTec AG
Microsoft Corporation successfully convinced the PTAB to institute an IPR against ParTec AG's patent, challenging claims related to heterogeneous computing and dynamic task remapping. The Board found a reasonable likelihood of unpatentability based on prior art combinations (Lippert, Budenske, Kambatla).
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.